{"id":31488,"date":"2025-04-09T18:00:46","date_gmt":"2025-04-09T10:00:46","guid":{"rendered":"https:\/\/flcube.com\/?p=31488"},"modified":"2025-04-09T18:00:47","modified_gmt":"2025-04-09T10:00:47","slug":"sichuan-biokin-launches-phase-iii-trial-for-bl-b01d1-in-urothelial-carcinoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31488","title":{"rendered":"Sichuan Biokin Launches Phase III Trial for BL-B01D1 in Urothelial Carcinoma"},"content":{"rendered":"\n

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506<\/a>) has announced the first patient enrollment in the Phase III study of its investigational bispecific antibody drug conjugate (ADC), BL-B01D1. This milestone marks significant progress in the development of novel therapies for patients with locally advanced or metastatic urothelial carcinoma (UC) who have failed previous platinum-based chemotherapy and PD-1\/PD-L1 inhibitor therapy.<\/p>\n\n\n\n

Drug Mechanism<\/strong>
BL-B01D1 is a bispecific ADC targeting both EGFR and HER3, designed to deliver cytotoxic agents directly to cancer cells expressing these receptors. This dual targeting approach enhances the drug’s ability to bind to tumor cells and deliver therapeutic effects, making it a promising candidate for the treatment of UC.<\/p>\n\n\n\n

Clinical Trial Progress<\/strong>
The Phase III study will evaluate the efficacy and safety of BL-B01D1 in patients with UC who have not responded to standard treatments. The trial aims to provide critical data supporting the drug’s potential to improve outcomes for patients with this aggressive form of cancer.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced the first patient enrollment in…<\/p>\n","protected":false},"author":1,"featured_media":31489,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[151,16,62,857],"class_list":["post-31488","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-biokin-pharmaceutical","tag-cancer","tag-clinical-trial-approval-initiation","tag-sha-688506"],"yoast_head":"\nSichuan Biokin Launches Phase III Trial for BL-B01D1 in Urothelial Carcinoma - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced the first patient enrollment in the Phase III study of its investigational bispecific antibody drug conjugate (ADC), BL-B01D1. This milestone marks significant progress in the development of novel therapies for patients with locally advanced or metastatic urothelial carcinoma (UC) who have failed previous platinum-based chemotherapy and PD-1\/PD-L1 inhibitor therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31488\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sichuan Biokin Launches Phase III Trial for BL-B01D1 in Urothelial Carcinoma\" \/>\n<meta property=\"og:description\" content=\"China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced the first patient enrollment in the Phase III study of its investigational bispecific antibody drug conjugate (ADC), BL-B01D1. This milestone marks significant progress in the development of novel therapies for patients with locally advanced or metastatic urothelial carcinoma (UC) who have failed previous platinum-based chemotherapy and PD-1\/PD-L1 inhibitor therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31488\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-09T10:00:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-09T10:00:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0918-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31488#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31488\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sichuan Biokin Launches Phase III Trial for BL-B01D1 in Urothelial Carcinoma\",\"datePublished\":\"2025-04-09T10:00:46+00:00\",\"dateModified\":\"2025-04-09T10:00:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31488\"},\"wordCount\":179,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31488#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0918-png.webp\",\"keywords\":[\"Biokin Pharmaceutical\",\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"SHA: 688506\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31488#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31488\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31488\",\"name\":\"Sichuan Biokin Launches Phase III Trial for BL-B01D1 in Urothelial Carcinoma - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31488#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31488#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0918-png.webp\",\"datePublished\":\"2025-04-09T10:00:46+00:00\",\"dateModified\":\"2025-04-09T10:00:47+00:00\",\"description\":\"China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced the first patient enrollment in the Phase III study of its investigational bispecific antibody drug conjugate (ADC), BL-B01D1. This milestone marks significant progress in the development of novel therapies for patients with locally advanced or metastatic urothelial carcinoma (UC) who have failed previous platinum-based chemotherapy and PD-1\\\/PD-L1 inhibitor therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31488#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31488\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31488#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0918-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0918-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sichuan Biokin Launches Phase III Trial for BL-B01D1 in Urothelial Carcinoma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31488#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sichuan Biokin Launches Phase III Trial for BL-B01D1 in Urothelial Carcinoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sichuan Biokin Launches Phase III Trial for BL-B01D1 in Urothelial Carcinoma - Insight, China's Pharmaceutical Industry","description":"China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced the first patient enrollment in the Phase III study of its investigational bispecific antibody drug conjugate (ADC), BL-B01D1. This milestone marks significant progress in the development of novel therapies for patients with locally advanced or metastatic urothelial carcinoma (UC) who have failed previous platinum-based chemotherapy and PD-1\/PD-L1 inhibitor therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31488","og_locale":"en_US","og_type":"article","og_title":"Sichuan Biokin Launches Phase III Trial for BL-B01D1 in Urothelial Carcinoma","og_description":"China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced the first patient enrollment in the Phase III study of its investigational bispecific antibody drug conjugate (ADC), BL-B01D1. This milestone marks significant progress in the development of novel therapies for patients with locally advanced or metastatic urothelial carcinoma (UC) who have failed previous platinum-based chemotherapy and PD-1\/PD-L1 inhibitor therapy.","og_url":"https:\/\/flcube.com\/?p=31488","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-09T10:00:46+00:00","article_modified_time":"2025-04-09T10:00:47+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0918-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31488#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31488"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sichuan Biokin Launches Phase III Trial for BL-B01D1 in Urothelial Carcinoma","datePublished":"2025-04-09T10:00:46+00:00","dateModified":"2025-04-09T10:00:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31488"},"wordCount":179,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31488#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0918-png.webp","keywords":["Biokin Pharmaceutical","Cancer","Clinical trial approval \/ initiation","SHA: 688506"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31488#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31488","url":"https:\/\/flcube.com\/?p=31488","name":"Sichuan Biokin Launches Phase III Trial for BL-B01D1 in Urothelial Carcinoma - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31488#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31488#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0918-png.webp","datePublished":"2025-04-09T10:00:46+00:00","dateModified":"2025-04-09T10:00:47+00:00","description":"China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced the first patient enrollment in the Phase III study of its investigational bispecific antibody drug conjugate (ADC), BL-B01D1. This milestone marks significant progress in the development of novel therapies for patients with locally advanced or metastatic urothelial carcinoma (UC) who have failed previous platinum-based chemotherapy and PD-1\/PD-L1 inhibitor therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31488#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31488"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31488#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0918-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0918-png.webp","width":1080,"height":608,"caption":"Sichuan Biokin Launches Phase III Trial for BL-B01D1 in Urothelial Carcinoma"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31488#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sichuan Biokin Launches Phase III Trial for BL-B01D1 in Urothelial Carcinoma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0918-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31488","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31488"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31488\/revisions"}],"predecessor-version":[{"id":31490,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31488\/revisions\/31490"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31489"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31488"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31488"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31488"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}